^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Inhibigen (MMP9FS)
i
Other names: MMP9FS
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Genocea
Drug class:
Immunostimulant
Related drugs:
almost3years
The PLANET manufacturing process reproducibly generates high-quality neoantigen-targeted peripheral T cells (NPTs) for adoptive T cell therapy in the TiTAN clinical trial (AACR 2022)
Patient-specific neoAgs against which their T cells were responsive were identified with ATLAS, and up to 30 neoAgs were prioritized for manufacture; pro-tumor Inhibigens™ were excluded. NPTs can routinely be manufactured in a GMP setting to treat patients with solid tumors. By expanding fresh, non-exhausted NeoAg-specific T cells with known tumor specificity from the periphery, GEN-011 has the potential to provide clinical benefits of TIL with greater accessibility and minimal irrelevant T cells. The TiTAN trial is ongoing.
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
GEN-011 • Inhibigen (MMP9FS)
almost3years
ATLAS-identified Inhibigen-specific responses accelerate tumor growth in mouse melanoma and pancreatic cancer (AACR 2022)
Genocea’s GEN-011 neoantigen-targeted peripheral T cell (NPT) therapy candidate, designed using ATLAS-identified neoantigens and omitting Inhibigens, is being evaluated in an ongoing clinical trial (NCT04596033). Continued exploration of mechanisms of action of Inhibigen-specific responses may reveal new paradigms of cancer immune evasion. 1H Lam et al, Cancer Discov 2021;11:1-18
Preclinical
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
GEN-011 • Inhibigen (MMP9FS)
Share via
